Karihtala, P. 2025. How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?. Acta Oncologica. 64, (Jun. 2025), 815–829. DOI:https://doi.org/10.2340/1651-226X.2025.43645.